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Haddad GE, Saunders LJ, Crosby SD, Carles M, del Monte F,
King K, Bristow MR, Spinale FG, Macgillivray TE, Semigran MJ,
Dec GW, Williams SA, Hajjar RJ, Gwathmey JK. Human cardiac-
specific cDNA array for idiopathic dilated cardiomyopathy: sex-related
differences. Physiol Genomics 33: 267–277, 2008. First published Feb-
ruary 26, 2008; doi:10.1152/physiolgenomics.00265.2007.—Idiopathic
dilated cardiomyopathy (IDCM) constitutes a large portion of patients
with heart failure of unknown etiology. Up to 50% of all transplant
recipients carry this clinical diagnosis. Female-specific gene expres-
sion in IDCM has not been explored. We report sex-related differ-
ences in the gene expression profile of ventricular myocardium from
patients undergoing cardiac transplantation. We produced and se-
quenced subtractive cDNA libraries, using human left ventricular
myocardium obtained from male transplant recipients with IDCM and
nonfailing human heart donors. With the resulting sequence data, we
generated a custom human heart failure microarray for IDCM con-
taining 1,145 cardiac-specific oligonucleotide probes. This array was
used to characterize RNA samples from female IDCM transplant
recipients. We identified a female gene expression pattern that con-
sists of 37 upregulated genes and 18 downregulated genes associated
with IDCM. Upon functional analysis of the gene expression pattern,
deregulated genes unique to female IDCM were those that are in-
volved in energy metabolism and regulation of transcription and
translation. For male patients we found deregulation of genes related
to muscular contraction. These data suggest that 1) the gene expres-
sion pattern we have detected for IDCM may be specific for this
disease and 2) there is a sex-specific profile to IDCM. Our observa-
tions further suggest for the first time ever novel targets for treatment
of IDCM in women and men.
gene expression; heart failure; IDCM markers
APPROXIMATELY FIFTY PERCENT of all heart transplant recipients
have idiopathic dilated cardiomyopathy (IDCM). About
4,900,000 Americans (2,400,000 males and 2,500,000 fe-
males) have IDCM, the incidence of which approaches 10 per
1,000 individuals after age 65 (3, 4). During the course of the
disease, myocardial contractile function steadily decreases.
Recent investigations have suggested that there may be myo-
cardial properties and/or hormonal environments unique to
women or men that contribute to atypical clinical presentation
and clinical outcomes. Despite its being well accepted that
women suffering from IDCM often have clinical presentations
differing from those of men with a similar cardiac condition,
little is known about the etiology of these sex-related differ-
ences.
In a study by Carroll et al. (15) examining left ventricle
hypertrophy caused by aortic stenosis, women had smaller,
thicker-walled ventricles despite outflow obstruction similar to
that in men. After diagnosis of nonischemic heart failure,
women fare somewhat better than men, but 15% survive
beyond 8–12 yr after diagnosis (3, 4). The average survival
after diagnosis of end-stage heart failure is 5 yr for the male
population.
Most studies on sex-related differences have used animal
models. Studies using transgenic murine and/or rat models of
heart failure have shown that females have less cardiac remod-
eling, ventricular dysfunction, and pathological change and an
increased survival advantage over males (20, 21, 23, 28, 37, 44,
50, 61, 66). Two such studies have suggested that female sex
hormones may play a protective role in heart failure. A female
phenotype can be mimicked by the use of estradiol in males
(11, 20, 66). Conversely, a murine study using testosterone
infusion in ovariectomized transgenic females showed in-
creased cardiac mass and fibrosis (44). An additional study
using male mice with cardiac overexpression of 2-adren-
ergic receptors showed a reduction in heart failure pheno-
type from orchiectomy (23). These results suggest an addi-
tional contribution by testicular male hormones to the pro-
gression of the cardiomyopathic phenotype in specific
transgenic models. Despite nonhuman research to date,
sex-related differences responsible for the better prognosis
of human females with heart failure have not yet been
clearly established.
The structural and functional changes that occur in IDCM
hearts in both men and women are most likely due to changes
in gene and protein expression. In a recent microarray study by
Barth et al. (6), a common gene expression signature for dilated
cardiomyopathy (DCM) in humans consisting of 27 genes was
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identified. In this study, sex-related differences that may occur
in a DCM-specific gene expression pattern were not addressed.
Despite these studies on human tissues and animal models
thought to mimic this disease, a clear sex-specific profile for
IDCM has yet to be determined. Human cardiac tissue studies
have been particularly fraught with discrepancies between
research groups, with noted differences from animal models (5,
7, 8, 10, 22, 24, 26, 34, 35, 39, 47, 49, 56, 58, 62, 70, 71).
Factors contributing to these discrepancies may include the
lack of quality samples from which good-quality RNA can be
obtained as well as the lack of access to medical histories. In
addition, absent from many studies are normal, sex- and
age-matched controls. We have, in the present study, rigor-
ously addressed these issues.
Microarray technology is capable of screening vast numbers
of genes, or entire genomes, for differential expression. Several
investigators have screened samples on nonspecific genome
arrays in order to identify deregulated genes (58). We exam-
ined the gene expression profile of diseased myocardium from
female and male patients with IDCM and control samples from
age- and race-matched donors by means of subtractive hybrid-
ization and gene microarray technology. To focus only on
genes that are potentially involved in IDCM, we have devel-
oped a heart-specific array by performing subtractive hybrid-
ization in order to preselect differentially expressed clones. By
using this approach, we were able to produce a focused
microarray containing both up- and downregulated genes,
including rare genes expressed at low levels in the nonfailing
and failing human heart. The array was used to test the
hypothesis that 1) IDCM has a specific gene profile and 2)
there are sex-specific differences in the expression profile of a
critical set of genes that might be important markers of heart
disease in men and women. We have identified putative sex-
specific differences in the gene expression pattern that charac-
terize the IDCM state. The gene expression differences in the
female samples may be indicative of sex-linked disparities in
the pathophysiology and potentially even the pathogenesis of
heart failure. Identified markers might then serve to specify
proteins that might be used as drug target candidates in female
and male heart failure patients.
MATERIALS AND METHODS
Human cardiac samples. Patient consent was obtained from all
transplant recipients. Family consent was provided for brain-dead
organ donors (normal control subjects). The hearts from brain-dead
organ donors with normal cardiac function were not used for trans-
plantation because of cardiac arrest with resuscitation, blood transfu-
sion, or lack of a suitable recipient. The clinical characteristics of the
IDCM patients are summarized in Supplemental Table S1.1 The
average age of the five male and six female IDCM patients was 57 
6.5 and 48  14.8 yr, respectively (P  0.24), and of the average
age-matched nonfailing male and female donors was 58  5.5 and
57  4.5 yr (P  0.66).
At the time of tissue procurement, hearts were excised and placed
in Wisconsin cardioplegic solution, placed on ice, and transported to
the laboratory. The hearts were examined and sectioned by a cardi-
ologist. Sections were snap frozen. Transplant recipient or donor
information was then entered into a secure database.
RNA isolation. Left ventricle tissue was pulverized in liquid nitro-
gen, placed in TRIzol reagent, and immediately homogenized with a
rotor-stator homogenizer. Total RNA was isolated according to the
manufacturer’s instructions (Invitrogen, Carlsbad, CA) with the fol-
lowing exceptions. An additional extraction with phenol (pH 4.3)-
chloroform was performed as well as an additional isopropanol
precipitation to further purify the RNA.
For each sample, messenger RNA (mRNA) was purified from 700
g of total RNA sample with the Poly(A) Pure mRNA Isolation Kit
(Ambion, Austin, TX) according to the manufacturer’s instructions. In
addition, mRNA was ethanol precipitated and washed once with 70%
ethanol for purification and concentration.
Microarray production. All contigs representing genes derived
from both forward and reverse human subtracted cDNA libraries,
identified through NCBI database queries, were chosen for production
1 The online version of this article contains supplemental material.
Fig. 1. Functional analysis of genes identified in the forward and reverse
subtracted cDNA libraries. Libraries were constructed from pooled male
idiopathic dilated cardiomyopathy (IDCM) and pooled male donor left ventri-
cle tissue (n  4 and n  10, respectively). The forward subtracted IDCM
cDNA library is enriched for genes that are increased in expression levels or
turned on during IDCM. Conversely, the reverse subtracted cDNA library is
enriched for genes that are decreased or turned off during IDCM. ECM,
extracellular matrix.
268 IDCM: HUMAN SEX-SPECIFIC cDNA ARRAY
Physiol Genomics • VOL 33 • www.physiolgenomics.org
Downloaded from journals.physiology.org/journal/physiolgenomics (073.004.114.249) on July 15, 2021.
of a heart failure oligo microarray. One hundred fifteen sequences not
identified through subtractive hybridization, but thought to play a role
in heart failure according to recent published microarray data (5, 26,
35, 58), were included in the microarray as additional oligonucleotide
probes. To construct a gene-specific microarray, we designed 70-mer
oligonucleotide array elements. Oligonucleotides were designed from
the full-length sequences, if available, with arrayoligoselector (12)
and were synthesized by using standard methods by illumina (San
Table 1. Differentially regulated genes in female IDCM patient samples




ACO2 Aconitase 2 BC014092 Energetics & metabolism 6.9
TTN Titin NM_003319 Ca2 binding & muscle contraction/structure 5.5
GPI Glucose phosphate isomerase NM_000175 Energetics & metabolism (carbohydrate) 5.1
HSPA1A Heat shock 70-kDa protein 1A NM_005345 Stress 5.0
FSTL3 Follistatin-like 3 NM_005860 Cell growth/ECM 4.0
IgG1L Immunoglobulin  heavy chain Y14737 Immune response 3.8
HSPCB Unknown CN355913 Unknown 3.5
NPPA Natriuretic peptide precursor A BC005893 Regulation of blood pressure 3.4
LGMN Legumain NM_005606 Degradation/apoptosis 2.9
UBE1 Ubiquitin-activating enzyme E1 BC013041 Degradation/apoptosis 2.9
CD81 CD81 antigen BC002978 Cell growth/ECM 2.8
Gup1 GRINL1A complex protein 2 precursor AY208913 Unknown 2.6
NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1 BC015645 Energetics & metabolism 2.4
CTGF Connective tissue growth factor NM_001901 Cell growth/ECM 2.2
ACTN1 -Actinin X15804 Cytoskeleton 2.2
DPT Dermatopontin NM_001937 Cell Growth/ECM 2.1
RTN4 Reticulon 4 BC010737 Degradation/apoptosis (proapoptosis) 2.1
IGFBP2 Insulin-like growth factor binding protein 2 BC009902 Cell growth/ECM 2.1
LTBP2 Latent transforming growth factor- binding protein Z37976 Cell growth/ECM 2.1
COL16A1 Collagen type XVI 1 S57132 Cell growth/ECM 2.0
GNB2 Guanine nucleotide binding protein  polypeptide 2 BC010073 Signal transduction 2.0
ACAT1 Acetyl-coenzyme A acetyltransferase 1 NM_000019 Energetics & metabolism (lipid) 2.0
HLA-DRB1 Major histocompatibility complex class II DR 3 BC008403 Immune response 1.9
SDHA Succinate dehydrogenase complex, subunit A, flavoprotein BC001380 Energetics & metabolism 1.9
HSPA5 Unknown AL541667 Unknown 1.8
ACTN2 Actinin 2 NM_001103 Cytoskeleton 1.8
MDH1 Malate dehydrogenase 1, NAD (soluble) NM_005917 Energetics & metabolism 1.8
VDAC3 Voltage-dependent anion channel 3 BC056870 Ion transport 1.8
LOC161247 Similar to CG10671-like NM_203402 Unknown 1.8
CKM Creatine kinase muscle AY335559 Energetics & metabolism 1.7
CSRP1 Cysteine and glycine-rich protein 1 NM_004078 Unknown 1.7
EGFL7 EGF-like-domain NM_016215 Ca2	 binding & muscle contraction/structure 1.7
PCBP2 Poly(rC) binding protein 2 NM_005016 Energetics & metabolism 1.7
PRDX2 Peroxiredoxin 2 BC039428 Stress 1.7
ACTC Actin, , cardiac muscle BC009978 Cytoskeleton 1.6
ACADM Unknown CN277078 Unknown 1.5
MYH7 Myosin heavy chain CF553070 Ca2 binding & muscle contraction/structure 2.5
Downregulated genes
PLA2G2A Phospholipase A2 group IIA BC005919 Energetics & metabolism (lipid) 9.0 (0.11)
MUSTN1 Musculoskeletal embryonic nuclear protein 1 NM_205853 Unknown 3.3 (0.31)
ADH1B Alcohol dehydrogenase IB NM_000668 Energetics & metabolism (alcohol) 2.9 (0.35)
G0S2 Lymphocyte G0/G1 switch gene BC009694 Immune response 2.5 (0.40)
CD36 CD36 antigen NM_000072 Signal transduction 
1.9 (0.53)
SELENBP1 Selenium binding protein 1 NM_003944 Unknown 
1.9 (0.52)
JUNB jun B protooncogene BC009466 Regulation transcription/translation 
1.5 (0.68)
APOD Apolipoprotein D NM_001647 Energetics & metabolism (lipid) 1.8 (0.56)
PYGM Highly similar to glycogen phosphorylase muscle form AK056607 Energetics & metabolism (carbohydrate) 1.8 (0.56)
FOS Unknown BX458870 Unknown 
1.1 (0.90)
CD59 CD59 antigen NM_203329 Immune response 1.7 (0.59)
MTHFD2 NAD-dependent methylene tetrahydrofolate dehydrogenase
cyclohydrolase
X16396 Energetics & metabolism (1-carbon compound) 
1.7 (0.58)
MYL4 Myosin light polypeptide 4, alkali, atrial, embryonic NM_002476 Ca2	 binding & muscle contraction/structure 1.7 (0.57)
GPD1L Glycerol-3-phosphate dehydrogenase 1 BC028726 Energetics & metabolism (carbohydrate) 
1.7 (0.57)
S100A4 S100 calcium binding protein A4 NM_002961 Ca2	 binding & muscle contraction/structure 
1.3 (0.80)
SH3BGRL3 SH3 domain binding glutamic acid-rich protein-like 3 AF247790 Unknown 
1.1 (0.90)
FBLP-1 Unknown AK130732 Unknown 
1.6 (0.61)
LDB3 LIM domain binding 3 BC010929 Ca2	 binding & muscle contraction/structure 
1.5 (0.67)
Genes up- or downregulated (1.8-fold) in at least 3 of 6 female idiopathic dilated cardiomyopathy (IDCM) patient samples are shown. Fold change represents
mean fold change in the 6 female IDCM patients. Genes in bold were also found to be up- or downregulated (1.8-fold) in at least 3 of 5 male IDCM patient
samples. ECM, extracellular matrix.
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Diego). The oligonucleotides were dissolved at a concentration of 50
mM in 3 SSC with 0.75 M betaine and were printed in duplicate on
MWG Epoxy slides (MWG Biotech, Ebersburg, Germany) by a
locally constructed linear servo arrayer (after the DeRisi model; Ref.
41). A total of 1,145 genes were represented on the heart-specific
microarray along with 6 Escherichia coli “ArrayControl” oligonucle-
otides (Ambion) representing sequences that do not hybridize to
mammalian sequences (total 1,151). Oligonucleotides were spotted in
triplicate onto epoxy-coated slides obtained from MWG (Germany)
and stored at 
20°C.
cDNA synthesis and microarray hybridization. cDNA was synthe-
sized from 2 g of total RNA isolated from left ventricle tissue of
each IDCM transplant recipient (n  11) or pooled male or female
nonfailing left ventricle control sample (n  10 per sex). cDNA
synthesis and hybridization were performed with the 3DNA Array
900 Detection System (Genisphere, Hatfield, PA), following the
manufacturer’s instructions with modifications. A total of two tech-
nical replicates for each patient were performed (dye swap) to correct
for any bias introduced by the Cy3 and Cy5 fluorescent dendrimers.
Slides were scanned immediately after hybridization on a ScanArray
Express HT Scanner (PerkinElmer) to detect Cy3 and Cy5 fluores-
cence. Laser power was kept constant, and photomultiplier tube
(PMT) values were set for optimal intensity with minimal background
(high-PMT scan). An additional scan was done for each slide with the
PMT such that 1% of the elements are saturated (low-PMT scan) to
characterize spots that were saturated in the high-PMT scan. Gridding
and analysis of images were performed with scanarray software
express version 3.0 (PerkinElmer).
Microarray data analysis (normalization). Values corresponding to
the fluorescence intensity for each oligonucleotide spot were obtained
and imported into GeneSpring 7.1 software (Agilent, Redwood City,
CA). Local background fluorescence intensity was subtracted from
individual spot fluorescence intensities. The mean signal and control
intensities of the on-slide duplicate spots were calculated. A Lowess
curve was fit to the log-intensity vs. log-ratio plot. Twenty percent of
the data was used to calculate the Lowess fit at each point. This curve
was used to adjust the control value for each measurement. If the
control channel was lower than 10 relative fluorescence units (RFU),
then 10 was used instead. Mean signal to Lowess-adjusted controlled
ratios were calculated. The cross-chip averages were derived from the
antilog of the mean of the natural log ratios across the two microarrays
(technical replicates-dye swaps).
Subtractive hybridization. With the technique of subtractive hy-
bridization, both a forward (IDCM minus nonfailing) and a reverse
(nonfailing minus IDCM) subtracted cDNA library were constructed,
following the manufacturer’s instructions (Clontech, Mountain View,
CA). Each library was constructed with pooled mRNA from left
ventricle tissue of 6 male IDCM transplant recipients and pooled
mRNA from 10 nonfailing age-matched donors. The forward sub-
tracted IDCM cDNA library is enriched for genes that are increased in
expression levels or turned on during IDCM. Conversely, the reverse
subtracted cDNA library is enriched for genes that are decreased or
turned off during IDCM. One thousand clones were randomly chosen
from each library, PCR amplified, and sequenced on a single-pass
basis to produce an expressed sequence tag (EST) for each clone. An
alignment (SeqMan, DNASTAR, Madison, WI) was performed with
all EST sequences from each subtracted cDNA library, and a contig (a
collection of ESTs representing the same gene) was generated for
each gene identified. Sequences were identified through NCBI data-
base queries.
Microarray data filtering. Data were filtered in the following
manner. 1) Oligonucleotide elements that received a “present” call
(intensity 200 RFU or local signal/background 2) by the ScanAr-
ray software in at least half the patients in either Cy3 or Cy5 were
identified (1,037 genes), and all others were excluded from the
analysis. 2) The genes that demonstrated a CV 30% between the dye
swaps for 70% of the patients were selected. 3) Genes that showed
1.8-fold up- or downregulation in three of five male and three of six
female transplant recipients compared with the pooled male or female
nonfailing control samples, respectively, were selected.
Real-time quantitative RT-PCR. To confirm the expression patterns
detected by our microarray, we randomly selected 39 genes from the
pool of deregulated genes identified in male and female IDCM
samples for further analysis by means of quantitative RT-PCR. The
reactions characterized RNA derived from pooled IDCM male (n 
5), pooled female (n  6), or nonfailing pooled RNA male or female
sample (n  20). Two-step RT-PCR was performed with 10 ng of
total RNA per reaction. Triplicate aliquots of each RNA sample were
used in the same reactions. All samples were normalized to 18S rRNA
as an internal control. For all experimental samples, the relative fold
Table 2. Differentially regulated genes in both female and male IDCM patient samples
Common Name Description Accession No. Function
Upregulated genes
ACO2 Aconitase 2 BC014092 Energetics & metabolism
TTN Titin NM_003319 Ca2	 binding & muscle contraction/structure
GPI Glucose phosphate isomerase NM_000175 Energetics & metabolism (carbohydrate)
HSPA1A Heat shock 70-kDa protein 1A NM_005345 Stress
FSTL3 Follistatin-like 3 NM_005860 Cell growth/ECM
HSPCB Unknown CN355913 Unknown
NPPA Natriuretic peptide precursor A BC005893 Regulation of blood pressure
LGMN Legumain NM_005606 Degradation/apoptosis
CTGF Connective tissue growth factor NM_001901 Cell growth/ECM
DPT Dermatopontin NM_001937 Cell growth/ECM
COL16A1 Collagen type XVI 1 S57132 Cell growth/ECM
HLA-DRB1 Major histocompatibility complex class II DR 3 BC008403 Immune response
MYH7 Myosin heavy chain CF553070 Ca2	 binding & muscle contraction/structure
Downregulated genes
PLA2G2A Phospholipase A2 group IIA BC005919 Energetics & metabolism (lipid)
MUSTN1 Musculoskeletal embryonic nuclear protein 1 NM_205853 Unknown
ADH1B Alcohol dehydrogenase IB NM_000668 Energetics & metabolism (alcohol)
G0S2 Lymphocyte G0/G1 switch gene BC009694 Immune response
APOD Apolipoprotein D NM_001647 Energetics & metabolism (lipid)
PYGM Highly similar to glycogen phosphorylase muscle form AK056607 Energetics & metabolism (carbohydrate)
Genes up- or downregulated (1.8-fold) in both female (3 of 6) and male (3 of 5) IDCM patient samples are shown.
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difference of each gene was determined compared with the pooled
nonfailing male or female reference sample by means of the Ct
(threshold cycle) method (Applied Biosystems).
Western blot analysis. Sarco(endo)plasmic reticulum Ca2	-ATPase
(SERCA) protein levels were assessed by Western blot technique.
Two hundred micrograms of total protein was used for each sample
isolated from the left ventricular tissue of a human male donor, a
human female donor, a human male donor with idiopathic cardiomy-
opathy, or a human female donor with idiopathic cardiomyopathy.
Tissue lysates were matched for protein concentration, separated by
SDS-PAGE, and transferred onto nitrocellulose membranes. After
blocking in 5% non-fat milk in TBST (10 mM Tris, 150 mM NaCl,
0.1% Tween 20), the membranes were incubated with specific anti-
bodies to SERCA2a (Cell Signaling Technology) overnight at 4°C.
Afterward, membranes were washed three times in TBST, incubated
with appropriate secondary antibody conjugated to horseradish per-
oxidase (Cell Signaling Technology) for 2 h, and then washed three
times with TBST. Bands were visualized by Chemiluminescence
(Renaissance, NEN Life Science Products). Relative specific protein
levels between IDCM and nonfailing donor samples were obtained
with NIH densitometry Image software and normalized.
RESULTS
The objective of this study was to utilize a focused gene
discovery approach to identify genes whose expression is
significantly altered in IDCM and to identify an expression
pattern in female vs. male IDCM transplant recipients. We
created both a forward (IDCM minus control) and a reverse
(control minus IDCM) subtracted cDNA library and sequenced
1,000 randomly selected clones from each. Sequence clustering
analysis produced 535 contigs (consensus sequence of clus-
tered ESTs representing 1 gene) unique to the forward sub-
tracted library (upregulated) and 495 contigs uniquely repre-
sented in the reverse subtracted library (downregulated). Se-
quences identified by means of BLAST alignment to the
GenBank databases showed 95–100% homology at the nucleic
acid level. Of the identified contigs, 75% had an assigned
function.
The gene representation based on functional groups for each
subtracted library is shown in Fig. 1. Genes of unknown
function make up 29% and 22% of the forward and reverse
subtracted libraries, respectively. Of the 157 contigs of un-
known function found in the forward library, 133 are unique to
the forward subtracted cDNA library (i.e., not found in the
reverse subtracted cDNA library). Likewise, 84 of 108 con-
tigs of unknown function are unique to the reverse sub-
tracted cDNA library. As one might expect, a large propor-
tion of genes (18%) associated with cellular growth and the
extracellular matrix were identified in the forward library as
opposed to only 4% in the reverse library. This expression
pattern may be indicative of ventricular remodeling due to
IDCM.
Table 3. Differentially regulated genes in male IDCM patient samples
Common Name Description Accession No. Function
Upregulated genes
MFAP4 Microfibrillar-associated protein 4 NM_002404 Cell growth/ECM
LUM Lumican BC007038 Cell growth/ECM
ARGBP2 Arg/Abl-interacting protein BC011883 Cytoskeleton
COL16A1 Type XVI collagen -1 chain S57132 Cell growth/ECM
DPT Dermatopontin NM_001937 Cell growth/ECM
CTGF Connective tissue growth factor NM_001901 Cell growth/ECM
MYH7 Myosin heavy chain polypeptide 7 NM_000257 Ca2	 binding & muscle contraction/structure
TTN Titin NM_003319 Ca2	 binding & muscle contraction/structure
FLJ14437 Myopalladin NM_032578 Ca2	 binding & muscle contraction/structure
FSTL3 Follistatin-like 3 NM_005860 Cell growth/ECM
GPI Glucose phosphate isomerase NM_000175 Energetics & metabolism
HLA-DRB Major histocompatibility complex class III BC008403 Unknown
ACO2 Aconitase 2 BC014092 Energetics & metabolism
ANK1 Ankyrin 1 AF005213 Cell growth/ECM
LGMN Legumain NM_005606 Degradation
SLC4A3 Solute carrier family 4_anion exchanger member 3 NM_005070 Ion transport
HSPCB Unknown CN355913 Unknown
Downregulated genes
MYH6 Myosin heavy chain polypeptide 6 NM_002471 Ca2	 binding & muscle contraction/structure
PLA2G2A Phospholipase A2_group IIA BC005919 Energetics & metabolism (lipid)
ADH1B Alcohol dehydrogenase IB NM_000668 Energetics & metabolism (alcohol)
MT1X Metallothionein BC032338 Metal ion binding
HRASLS3 HRAS-like suppressor 3 NM_007069 Unknown
PYGM Highly similar to glycogen phosphorylase muscle form AK056607 Energetics & metabolism (carbohydrate)
R1229 Unknown
TIMP4 Tissue inhibitor of metalloproteinase 4 NM_003256 Cell growth/ECM
MGC29729 Hypothetical protein BC032121 Unknown
MUSTN1 Musculoskeletal embryonic nuclear protein 1 NM_205853 Unknown
TRA1 Tumor rejection antigen BC066656 Stress
G0S2 Putative lymphocyte G0/G1 switch gene BC009694 Immune response
KCNK1 Potassium channel subfamily K-member 1 NM_002245 Ion transport
APOD Apolipoprotein D NM_001647 Energetics & metabolism (lipid)
IL13RA1 Interleukin 13 receptor -1 NM_001560 Signal transduction
Genes up- or downregulated (1.8-fold) in at least 3 of 5 male IDCM patient samples are shown.
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To further explore IDCM-specific gene expression patterns,
a human heart failure microarray was produced with our
subtracted hybridization gene data. All contig sequences with
both known and unknown function were used to produce an
oligonucleotide-based human heart failure microarray. As a
result, we created a focused heart failure gene array containing
1,145 heart-specific oligonucleotide probes.
To address the question of sex-specific gene expression in
IDCM left ventricle tissue, individual IDCM RNA (female n 
6; male n  5) were hybridized to our heart failure microarray
against a male or female standard created from pooled samples
of nonfailing female (n  10) or male (n  10) left ventricle
RNA samples. Table 1 lists 55 genes determined to be differ-
entially expressed in IDCM female patient samples (37 up-
regulated; 18 downregulated). Nineteen of those genes were
found to be significantly upregulated (13 genes) or downregu-
lated (6 genes) coordinately in the male patient samples, as
depicted in Table 2. We used the same stringent criteria in
males as in females for genes that were consistently and
significantly deregulated in DCM patients (i.e., genes showing
1.8-fold up- or downregulation in 3 of 5 male and 3 of 6
female transplant recipients compared with the pooled male or
female nonfailing control samples, respectively). Accordingly,
Table 3 lists 30 genes determined to be differentially regulated
in male IDCM patient samples (17 upregulated and 13 down-
regulated). No genes were found to be differentially regulated
paradoxically (in opposite direction) between the male and
female cohorts. Genes of known function were classified on the
basis of biological function according to a modified version of
the NCBI Gene Ontology (GO) classification scheme. The
functional classification scheme consisted of 11 categories and
subgroups within each category. Functional classifications
within the expression clusters of female and male patient
samples are illustrated in Fig. 2.
Comparison of differentially expressed genes in male and
female IDCM samples based on functional category showed a
female expression pattern. Genes encoding metabolic proteins
made up a majority of the female IDCM upregulated expres-
sion pattern (28%). The majority of these genes are involved in
oxidative phosphorylation (e.g., NADH dehydrogenase, malate
dehydrogenase 1, and succinate dehydrogenase) and regulation
of lipid and nucleic acid metabolism [e.g., acetyl-coenzyme A
acetyltransferase poly(rC) binding protein 2]. Insulin-like
growth factor binding protein 2 and latent transforming growth
Fig. 2. Functional analysis of genes found to be differentially expressed in male and female IDCM left ventricle tissue by means of microarray analysis.
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factor- binding protein were uniquely upregulated only in the
female cohort. Upregulation of these genes was not seen in the
male cohort. Genes found to be upregulated in both male and
female cohorts represented proteins involved in cell growth,
cell adhesion, and the extracellular matrix. This observation is
likely indicative of ventricular remodeling that occurs irrespec-
tive of sex. On the other hand, the male cohort showed a
marked upregulation of genes related to calcium binding and
muscular contraction compared with the female profile. In
particular, the gene expressions of myosin heavy chain
polypeptide 7, titin, and myopalladin were significantly ele-
vated in male IDCM patients. In the same line, we also found
fewer downregulations of gene expression related to calcium
binding and contraction in male IDCM vs. female IDCM
patients.
The most prevalent group of transcripts downregulated in
both the male and female cohorts were those involved with
lipid and carbohydrate metabolism. Apolipoprotein D and
phospholipase A2 were found to be coordinately downregu-
lated in both the male and female cohorts. Likewise, glycogen
phosphorylase (carbohydrate metabolism) was coordinately
downregulated in both male and female cohorts, whereas
glycerol-3-phosphate dehydrogenase 1 and NAD-dependent
methylene tetrahydrofolate dehydrogenase cyclohydrolase (in-
volved in 1-carbon metabolism) were uniquely downregulated
only in the female cohort. Transcripts involved in calcium
binding, muscle structure, and homeostasis including the S100
calcium binding protein A4, a LIM domain Ca2	 binding
protein, and myosin light polypeptide 4 showed significantly
lower levels of expression unique to the female data set.
Fig. 3. Comparison of expression levels obtained by microarray analysis and by real-time quantitative RT-PCR (Q-RT-PCR) of 39 selected genes. Fold
difference expression is represented for each pooled IDCM sample (female n  6; male n  5) relative to a pooled normal male or female control sample (n 
20). Positive numbers represent fold upregulated and negative numbers represent fold downregulated. Q-RT-PCR data were normalized to 18S rRNA. FD, female
donor; MD, male donor; ACO2, aconitase 2; APOD, apolipoprotein D; COL16A1, collagen type XVI 1; CTGF, connective tissue growth factor; DPT,
dermatopontin; G0S2, lymphocyte G0/G1 switch gene; GPI, glucose phosphate isomerase; MUSTN1, musculoskeletal embryonic nuclear protein 1; MYL4,
myosin light polypeptide 4, alkali, atrial, embryonic; TTN, titin; ADH1B, alcohol dehydrogenase IB; FSTL3, myopalladin; LGMN, legumain; RTN4, reticulon
4; ACAT1, acetyl-coenzyme A acetyltransferase 1; Gup1, GRINL1A complex protein 2 precursor; LTBP2, latent transforming growth factor- binding protein;
MDH1, malate dehydrogenase 1, NAD (soluble); SDHA, succinate dehydrogenase complex, subunit A, flavoprotein; UBE1, ubiquitin-activating enzyme E1;
ACTC, actin , cardiac muscle; ACTN1, -actinin; CD36, CD36 antigen; CD81, CD81 antigen; CSRP1, cysteine and glycine-rich protein 1; EGFL7,
EGF-like-domain; GNB2, guanine nucleotide binding protein  polypeptide 2; GPD1L, glycerol-3-phosphate dehydrogenase 1-like; IGFBP2, insulin-like growth
factor binding protein 2; LDB3, LIM domain binding 3; MTHFD2, NAD-dependent methylene tetrahydrofolate dehydrogenase cyclohydrolase; NDUFV1,
NADH dehydrogenase (ubiquinone) flavoprotein 1; PCBP2, poly(rC) binding protein 2.
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RT-PCR was used to confirm the relative expression patterns
of 39 randomly selected transcripts identified as differentially
expressed in IDCM by means of microarray analysis. Expres-
sion of 36 of the 39 genes (92.3%) tested by means of
quantitative RT-PCR reflected results obtained by microarray
analysis (see Fig. 3).
Furthermore, gene expression analysis of SERCA2a showed
this gene to be downregulated in male human transplant recip-
ients as assessed by microarray analysis. Western blot analysis
(Fig. 4) corresponded to the male gene expression pattern and
indicated an 88% decrease in protein content in the male
human heart failure samples. However, microarray analysis of
SERCA2a shows this gene to be upregulated in female human
transplant recipients. Western blot analysis (Fig. 4) shows a
48% increase in the SERCA2a of human IDCM female hearts
compared with the control hearts, which is in agreement with
the gene modulation data.
DISCUSSION
IDCM is a common etiology of heart muscle disease in both
male and female patients. Despite the fact that women suffer-
ing from IDCM often have clinical presentations and outcomes
differing from those of men with a similar cardiac condition,
little is known about the cellular or molecular basis of these
sex-related differences. Since the structural and functional
changes that occur in IDCM hearts are ultimately due to
changes in gene and protein expression, we have explored the
differences in myocardial male and female gene expression
patterns consequent to IDCM. The use of subtractive hybrid-
ization to produce a focused heart failure array along with array
hybridization of male and female myocardial RNA samples has
identified genes whose expression is significantly altered in
IDCM as well as an expression pattern unique to each sex
transplant recipient with IDCM.
Microarray technology has been used as a large-scale
genomic approach to decipher the molecular mechanisms in-
volved in physiological and pathological processes in various
animal or human tissues (1, 2, 5, 18, 19, 26, 30, 35, 56, 58). We
have used our human heart failure array to further quantify the
expression of gene products in female and male hearts conse-
quent to IDCM. Each individual heart failure sample was
normalized to sex-specific pooled nonfailing heart samples to
standardize for normal differences in expression values be-
tween male and female samples. We selected our IDCM
population, analyzing demographics as well as age matching
our control human heart samples. Controls were selected from
our human tissue repository that were the best matched on the
basis of echocardiographic study.
Differences in the literature may also reflect differences in
the techniques applied as well as data analysis approaches (14,
17, 25, 31, 33, 38, 43, 45, 48, 54, 65). We have applied a
focused approach to gene expression analysis consequent to
IDCM. We have created the first focused human heart failure
microarray containing 1,145 differentially expressed gene
probes. A random sample of genes demonstrated by microarray
to be deregulated was confirmed by RT-PCR with 92.3%
conformity. Using this stringent approach, we have identified
sex-specific gene expression patterns in female and male trans-
plant recipients with IDCM.
At the outset of this study, we anticipated that some of the
results would confirm the accuracy of our array based on
previous published observations. For example, natriuretic pep-
tide precursor A (NPPA) showed a high level of upregulation
in IDCM transplant recipients (i.e., male and female), support-
ing its role as a marker of myocardial stress (67). SERCA2a
was consistently downregulated in male samples and tended to
be upregulated in female samples. Western blot analysis dem-
onstrated an 88% decrease in protein content in male IDCM
samples compared with male control samples. In contrast, a
48% increase in SERCA2a protein content was observed in
female IDCM samples compared with control female samples.
This gene product is being targeted for molecular medicine
approaches and may warrant closer scrutiny. The high strin-
gency of the microarray analysis would exclude certain genes
that otherwise would show deregulation with a less stringent
analysis or Western blot assays. Thus the outset is affected by
the threshold for inclusion, which depends on the stringency
level predefined before analysis.
In addition to genes whose role in IDCM is well character-
ized, data were obtained identifying genes and families of
genes whose correlation with disease has not yet been reported.
Not surprisingly, there was a significant overlap of upregulated
genes (13 of 37 genes upregulated in female IDCM) between
male and female IDCM patients. Most of the genes coordi-
nately upregulated in both the male and female groups were
those involved in general cell growth and the extracellular
matrix, indicative of myocyte and ventricular remodeling com-
mon to both. The largest group of genes consistently upregu-
lated in IDCM female heart samples were those involved in
energy and metabolism (e.g., mitochondrial oxidative phos-
phorylation and ATP synthesis). DCM involves structural as
well as functional alterations leading to heart failure. Metabolic
cardiac stress is known to be associated with the development
of DCM, ultimately leading to an imbalance and heart failure.
Therefore, the differential gene regulation between sexes may
be reflected in a difference in the tolerance levels for the
disease between males and females.
In the stressed heart, metabolic remodeling precedes, trig-
gers, and sustains functional and structural remodeling (42, 51,
55, 59, 64). Adaptations to sustained heart stress can induce
changes in the metabolic machinery at a transcriptional and/or
a translational level of enzymes involved in metabolic path-
ways. Concomitant with an increase of gene expression of en-
Fig. 4. Western blot of sarco(endo)plasmic reticulum Ca2	 ATPase (SERCA)
of human male and female cardiomyocytes. Two hundred micrograms of total
protein was used for each sample. Relative specific protein levels between
IDCM and nonfailing donor samples were obtained with NIH densitometry
software (NIH Image). Human male donor (HMd) and human female donor
(HFd)  200 g of total protein isolated from human male donor left ventricle
tissue (normal). Human male IDCM [HM(DCM)] and human female IDCM
[HF(DCM)]  200 g of total protein isolated from human male patients
undergoing cardiac transplantation (IDCM).
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zymes associated with oxidative phosphorylation was an increase
in peroxiredoxin 2 in female-specific analysis, an enzyme
involved in the reduction of the oxygen radical hydrogen
peroxide (a destructive by-product of oxidative phosphoryla-
tion). This observation of deregulation of genes associated with
energy transduction and antioxidant activity unique to female
patients may suggest a higher level of metabolic adaptation in
female hearts due to stress, resulting in increased myocyte
survival. In fact, a proteomic study has shown that, in contrast
to aging male monkey hearts, hearts of female nonhuman
primates did not undergo reductions in the expression of
enzymes related to glycolysis, glucose oxidation, TCA cycle
and mitochondrial oxidative phosphorylation (69). This sup-
ports our data showing a higher metabolic capacity and energy
production of female hearts compared with male hearts, con-
ferring a better survival than males. More recently, the same
group, using DNA microarray, showed an upregulation of
phosphor-transferase genes in female monkeys, which are
related to glycolysis and glucose oxidation (53). In that regard,
the cDNA array data from our female cohort show that a major
deregulated gene group is related to metabolic disorders. Spe-
cifically, those that are related to glycolysis are downregulated,
while those related to oxidative phosphorylation are upregu-
lated. Such deregulation is specific to the female patients, since
the male patients did not exhibit it. Looking at the broader
picture regarding the signaling pathways, it seems that female
patients with IDCM have a downgraded glycolysis, so that the
source of energy production (ATP) may be shunted from
glycolysis toward other collateral pathways that feed into the
upregulated TCA or oxidative phosphorylation process. Such
inputs could be from fatty acid metabolism, ketone bodies,
amino acids, and their metabolites (e.g., creatine). Accord-
ingly, cardiomyopathy has been associated with mitochondrial
disease (32). It has been suggested that the supply side of heart
failure (i.e., myocardial energetics) is the most plastic and
easily restored (36, 52, 68). This might in part explain the
somewhat better outcomes for women with heart failure. We
previously demonstrated (27, 46) in a model of heart failure
that rescuing the normal phenotype is correlated with a return
toward normal myocardial energetics, sarcoplasmic reticulum
calcium cycling, and myofibrillar ATPase. This distinctive
better tolerance to failure exhibited by female IDCM vs. male
IDCM patients is congruent with larger upregulation of cal-
cium binding and fewer downregulations of muscle contraction
gene expressions in our male patients. This may be regarded as
an attempt to improve systolic function of the dilated heart in
the male, but it may also prove to be exhaustive of the cardiac
muscle’s energetics in the long term. Such energy burden is
aggravated with the large downregulation of gene expressions
related to energetics and metabolism in the male.
The link between abnormal heart metabolism and progres-
sion to heart failure has been well studied (27, 36, 42, 46, 51,
52, 55, 63, 64). It has been suggested that energy supply and
demand are pivotal in the development and progression of
heart failure (36, 42, 59, 64). There is striking evidence in
cancer cells that implicates a link between cell survival and
metabolism. Cancer cells have been shown to possess an
increased rate of glucose metabolism and oxidative phosphor-
ylation accompanied by a reduction in cell death when stressed
(29, 68). Perhaps female hearts possess a greater ability, due to
heightened metabolic adaptation, to maintain energy for con-
tractile function in a stressed heart, leading to less cardiac
dysfunction, cell death, and remodeling. The modulation of
energy metabolism to improve performance of dysfunctional
myocardium has been intensely studied (16, 55, 60). Pharma-
cological agents that increase myocardial substrate metabolism
and further couple this process with oxidative phosphorylation
have been shown to have beneficial effects in heart failure (9,
13, 16, 40, 42, 55, 57, 60). These data suggest that increased
compensatory mechanisms in female heart failure may lie in
increased or prolonged efficiency of metabolic adaptation.
Further study is needed to assess any increased beneficial
effects of metabolic modulation in female heart failure that
may improve metabolic/mechanical coupling.
In conclusion, we have identified molecular pathways that
may mediate sex differences in IDCM prognosis. One can
envision the future use of expression data in clinical trial
enrollments. Sex-specific differences in the expression profile
of critical genes could provide important indicators and diag-
nostic markers of heart failure progression in women as well as
men. Expression studies such as this one could serve to identify
genes encoding proteins that are drug target candidates in
female as well as male heart failure patients. In this study we
focused on end-stage IDCM. This may not reflect early stages
in diseased myocardium. Future exploration of gene expression
patterns in early states of diseased myocardium is warranted.
Ongoing work also includes race-related profiling of gene
expression levels.
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8. Beisvag V, Lehre PK, Midelfart H, Aass H, Geiran O, Sandvik AK,
Laegreid A, Komorowski J, Ellingsen O. Aetiology-specific patterns in
end-stage heart failure patients identified by functional annotation and
classification of microarray data. Eur J Heart Fail 8: 381–389, 2006.
9. Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K,
Khorrami P, Henderson GN, de Marco T, Chatterjee K. Improved
hemodynamic function and mechanical efficiency in congestive heart
275IDCM: HUMAN SEX-SPECIFIC cDNA ARRAY
Physiol Genomics • VOL 33 • www.physiolgenomics.org
Downloaded from journals.physiology.org/journal/physiolgenomics (073.004.114.249) on July 15, 2021.
failure with sodium dichloroacetate. J Am Coll Cardiol 23: 1617–1624,
1994.
10. Blackman IC, Bond M, Bowling A, Banning A, Dudley N, Elder A,
Martin A, Rai GS. Age and sex do not bias the use of angiotensin-
converting enzyme inhibitors in acute myocardial infarction and conges-
tive heart failure. J Am Geriatr Soc 51: 572–573, 2003.
11. Boheler KR, Volkova M, Morrell C, Garg R, Zhu Y, Margulies K,
Seymour AM, Lakatta EG. Sex- and age-dependent human transcrip-
tome variability: implications for chronic heart failure. Proc Natl Acad Sci
USA 100: 2754–2759, 2003.
12. Bozdech Z, Zhu J, Joachimiak MP, Cohen FE, Pulliam B, DeRisi JL.
Expression profiling of the schizont and trophozoite stages of Plasmodium
falciparum with a long-oligonucleotide microarray. Genome Biol 4: R9,
2003.
13. Bricaud H, Brottier L, Barat JL, Combe C, Boussens B, Bonnet J.
Cardioprotective effect of trimetazidine in severe ischemic cardiomyopa-
thy. Cardiovasc Drugs Ther 4, Suppl 4: 861–865, 1990.
14. Broude NE. Differential display in the time of microarrays. Expert Rev
Mol Diagn 2: 209–216, 2002.
15. Carroll JD, Carroll EP, Feldman T, Ward DM, Lang RM, Mc-
Gaughey D, Karp RB. Sex-associated differences in left ventricular
function in aortic stenosis of the elderly. Circulation 86: 1099–1107,
1992.
16. Chapados RA, Gruver EJ, Ingwall JS, Marsh JD, Gwathmey JK.
Chronic administration of cardiovascular drugs: altered energetics and
transmembrane signaling. Am J Physiol Heart Circ Physiol 263: H1576–
H1586, 1992.
17. Churchill GA. Fundamentals of experimental design for cDNA microar-
rays. Nat Genet 32, Suppl: 490–495, 2002.
18. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of
metastasis reveals an essential role for RhoC. Nature 406: 532–535, 2000.
19. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman
RN, Golub TR. Expression analysis with oligonucleotide microarrays
reveals that MYC regulates genes involved in growth, cell cycle, signal-
ing, and adhesion. Proc Natl Acad Sci USA 97: 3260–3265, 2000.
20. Du XJ. Gender modulates cardiac phenotype development in genetically
modified mice. Cardiovasc Res 63: 510–519, 2004.
21. Du XJ, Samuel CS, Gao XM, Zhao L, Parry LJ, Tregear GW.
Increased myocardial collagen and ventricular diastolic dysfunction in
relaxin deficient mice: a gender-specific phenotype. Cardiovasc Res 57:
395–404, 2003.
22. Ellinghaus P, Scheubel RJ, Dobrev D, Ravens U, Holtz J, Huetter J,
Nielsch U, Morawietz H. Comparing the global mRNA expression profile
of human atrial and ventricular myocardium with high-density oligonu-
cleotide arrays. J Thorac Cardiovasc Surg 129: 1383–1390, 2005.
23. Gao XM, Agrotis A, Autelitano DJ, Percy E, Woodcock EA, Jennings
GL, Dart AM, Du XJ. Sex hormones and cardiomyopathic phenotype
induced by cardiac beta 2-adrenergic receptor overexpression. Endocri-
nology 144: 4097–4105, 2003.
24. Gao Z, Xu H, DiSilvestre D, Halperin VL, Tunin R, Tian Y, Yu W,
Winslow RL, Tomaselli GF. Transcriptomic profiling of the canine
tachycardia-induced heart failure model: global comparison to human and
murine heart failure. J Mol Cell Cardiol 40: 76–86, 2006.
25. Gerhold DL, Jensen RV, Gullans SR. Better therapeutics through
microarrays. Nat Genet 32, Suppl: 547–551, 2002.
26. Grzeskowiak R, Witt H, Drungowski M, Thermann R, Hennig S,
Perrot A, Osterziel KJ, Klingbiel D, Scheid S, Spang R, Lehrach H,
Ruiz P. Expression profiling of human idiopathic dilated cardiomyopathy.
Cardiovasc Res 59: 400–411, 2003.
27. Gwathmey JK, Kim CS, Hajjar RJ, Khan F, DiSalvo TG, Matsumori
A, Bristow MR. Cellular and molecular remodeling in a heart failure
model treated with the beta-blocker carteolol. Am J Physiol Heart Circ
Physiol 276: H1678–H1690, 1999.
28. Haghighi K, Schmidt AG, Hoit BD, Brittsan AG, Yatani A, Lester
JW, Zhai J, Kimura Y, Dorn GW, MacLennan DH, Kranias EG.
Superinhibition of sarcoplasmic reticulum function by phospholamban
induces cardiac contractile failure. J Biol Chem 276: 24145–24152, 2001.
29. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100: 57–70,
2000.
30. Harrington CA, Rosenow C, Retief J. Monitoring gene expression using
DNA microarrays. Curr Opin Microbiol 3: 285–291, 2000.
31. Hess KR, Zhang W, Baggerly KA, Stivers DN, Coombes KR. Microar-
rays: handling the deluge of data and extracting reliable information.
Trends Biotechnol 19: 463–468, 2001.
32. Holmgren D, Wahlander H, Eriksson BO, Oldfors A, Holme E,
Tulinius M. Cardiomyopathy in children with mitochondrial disease;
clinical course and cardiological findings. Eur Heart J 24: 280 –288,
2003.
33. Holzman T, Kolker E. Statistical analysis of global gene expression data:
some practical considerations. Curr Opin Biotechnol 15: 52–57, 2004.
34. Horn S, Lueking A, Murphy D, Staudt A, Gutjahr C, Schulte K,
Konig A, Landsberger M, Lehrach H, Felix SB, Cahill DJ. Profiling
humoral autoimmune repertoire of dilated cardiomyopathy (DCM) pa-
tients and development of a disease-associated protein chip. Proteomics 6:
605–613, 2006.
35. Hwang JJ, Allen PD, Tseng GC, Lam CW, Fananapazir L, Dzau VJ,
Liew CC. Microarray gene expression profiles in dilated and hypertrophic
cardiomyopathic end-stage heart failure. Physiol Genomics 10: 31–44,
2002.
36. Ingwall JS, Nascimben L, Gwathmey JK. Heart failure: is the
pathology due to calcium overload or to mismatch in energy supply and
demand? In: Heart Failure: Basic Science and Clinical Aspects, edited
by Gwathmey JK, Briggs GM, and Allen PD. New York: Dekker, 1993,
p. 667–700.
37. Kadokami T, McTiernan CF, Kubota T, Frye CS, Feldman AM.
Sex-related survival differences in murine cardiomyopathy are associated
with differences in TNF-receptor expression. J Clin Invest 106: 589–597,
2000.
38. Kaminski N, Allard JD, Pittet JF, Zuo F, Griffiths MJ, Morris D,
Huang X, Sheppard D, Heller RA. Global analysis of gene expression in
pulmonary fibrosis reveals distinct programs regulating lung inflammation
and fibrosis. Proc Natl Acad Sci USA 97: 1778–1783, 2000.
39. Kittleson MM, Minhas KM, Irizarry RA, Ye SQ, Edness G, Breton
E, Conte JV, Tomaselli G, Garcia JG, Hare JM. Gene expression
analysis of ischemic and nonischemic cardiomyopathy: shared and
distinct genes in the development of heart failure. Physiol Genomics
21: 299 –307, 2005.
40. Kobayashi A, Masumura Y, Yamazaki N. L-Carnitine treatment for
congestive heart failure—experimental and clinical study. Jpn Circ J 56:
86–94, 1992.
41. Lashkari DA, DeRisi JL, McCusker JH, Namath AF, Gentile C,
Hwang SY, Brown PO, Davis RW. Yeast microarrays for genome wide
parallel genetic and gene expression analysis. Proc Natl Acad Sci USA 94:
13057–13062, 1997.
42. Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy
metabolism during cardiac hypertrophic growth. Heart Fail Rev 7: 175–
185, 2002.
43. Lemon WJ, Palatini JJ, Krahe R, Wright FA. Theoretical and experi-
mental comparisons of gene expression indexes for oligonucleotide arrays.
Bioinformatics 18: 1470–1476, 2002.
44. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T,
Hamanaka I, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y,
Nakanishi M, Adachi Y, Garbers DL, Fukamizu A, Nakao K. Andro-
gen contributes to gender-related cardiac hypertrophy and fibrosis in mice
lacking the gene encoding guanylyl cyclase-A. Endocrinology 145: 951–
958, 2004.
45. Liang P. A decade of differential display. Biotechniques 33: 338–44, 346,
2002.
46. Liao R, Nascimben L, Friedrich J, Gwathmey JK, Ingwall JS. De-
creased energy reserve in an animal model of dilated cardiomyopathy.
Relationship to contractile performance. Circ Res 78: 893–902, 1996.
47. Liew CC. Expressed genome molecular signatures of heart failure. Clin
Chem Lab Med 43: 462–469, 2005.
48. Livesey FJ. Strategies for microarray analysis of limiting amounts of
RNA. Brief Funct Genomic Proteomic 2: 31–36, 2003.
49. Margulies KB, Matiwala S, Cornejo C, Olsen H, Craven WA, Bed-
narik D. Mixed messages: transcription patterns in failing and recovering
human myocardium. Circ Res 96: 592–599, 2005.
50. Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE,
Schiebinger RJ. Androgen receptors mediate hypertrophy in cardiac
myocytes. Circulation 98: 256–261, 1998.
51. Neubauer S, Horn M, Naumann A, Tian R, Hu K, Laser M, Friedrich
J, Gaudron P, Schnackerz K, Ingwall JS. Impairment of energy metab-
olism in intact residual myocardium of rat hearts with chronic myocardial
infarction. J Clin Invest 95: 1092–1100, 1995.
52. O’Brien PJ, Gwathmey JK. Myocardial Ca2	- and ATP-cycling imbal-
ances in end-stage dilated and ischemic cardiomyopathies. Cardiovasc Res
30: 394–404, 1995.
276 IDCM: HUMAN SEX-SPECIFIC cDNA ARRAY
Physiol Genomics • VOL 33 • www.physiolgenomics.org
Downloaded from journals.physiology.org/journal/physiolgenomics (073.004.114.249) on July 15, 2021.
53. Qiu H, Tian B, Resuello RG, Natividad FF, Peppas A, Shen YT,
Vatner DE, Vatner SF, Depre C. Sex-specific regulation of gene expres-
sion in the aging monkey aorta. Physiol Genomics 29: 169–180, 2007.
54. Rao JS, Bond M. Microarrays: managing the data deluge. Circ Res 88:
1226–1227, 2001.
55. Saupe KW, Spindler M, Tian R, Ingwall JS. Impaired cardiac energetics
in mice lacking muscle-specific isoenzymes of creatine kinase. Circ Res
82: 898–907, 1998.
56. Sharma HS, Peters TH, Moorhouse MJ, van der Spek PJ, Bogers AJ.
DNA microarray analysis for human congenital heart disease. Cell Bio-
chem Biophys 44: 1–9, 2006.
57. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of
myocardial carbohydrate metabolism under normal and ischaemic condi-
tions. Potential for pharmacological interventions. Cardiovasc Res 33:
243–257, 1997.
58. Steenman M, Chen YW, Le CM, Lamirault G, Varro A, Hoffman E,
Leger JJ. Transcriptomal analysis of failing and nonfailing human hearts.
Physiol Genomics 12: 97–112, 2003.
59. Taegtmeyer H. Genetics of energetics: transcriptional responses in car-
diac metabolism. Ann Biomed Eng 28: 871–876, 2000.
60. Taegtmeyer H, Wilson CR, Razeghi P, Sharma S. Metabolic energetics
and genetics in the heart. Ann NY Acad Sci 1047: 208–218, 2005.
61. Tamura T, Said S, Gerdes AM. Gender-related differences in myocyte
remodeling in progression to heart failure. Hypertension 33: 676–680,
1999.
62. Tan FL, Moravec CS, Li J, Apperson-Hansen C, McCarthy PM,
Young JB, Bond M. The gene expression fingerprint of human heart
failure. Proc Natl Acad Sci USA 99: 11387–11392, 2002.
63. Tian R. Transcriptional regulation of energy substrate metabolism in
normal and hypertrophied heart. Curr Hypertens Rep 5: 454–458, 2003.
64. Tian R, Nascimben L, Kaddurah-Daouk R, Ingwall JS. Depletion of
energy reserve via the creatine kinase reaction during the evolution of
heart failure in cardiomyopathic hamsters. J Mol Cell Cardiol 28: 755–
765, 1996.
65. Tilstone C. DNA microarrays: vital statistics. Nature 424: 610–612,
2003.
66. van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ,
Doevendans PA. 17-Estradiol attenuates the development of pressure-
overload hypertrophy. Circulation 104: 1419–1423, 2001.
67. Vikstrom KL, Bohlmeyer T, Factor SM, Leinwand LA. Hypertrophy,
pathology, and molecular markers of cardiac pathogenesis. Circ Res 82:
773–778, 1998.
68. Warburg O. On the origin of cancer cells. Science 123: 309–314, 1956.
69. Yan L, Ge H, Li H, Lieber SC, Natividad F, Resuello RR, Kim SJ,
Akeju S, Sun A, Loo K, Peppas AP, Rossi F, Lewandowski ED,
Thomas AP, Vatner SF, Vatner DE. Gender-specific proteomic alter-
ations in glycolytic and mitochondrial pathways in aging monkey hearts.
J Mol Cell Cardiol 37: 921–929, 2004.
70. Yang J, Moravec CS, Sussman MA, DiPaola NR, Fu D, Hawthorn L,
Mitchell CA, Young JB, Francis GS, McCarthy PM, Bond M. De-
creased SLIM1 expression and increased gelsolin expression in failing
human hearts measured by high-density oligonucleotide arrays. Circula-
tion 102: 3046–3052, 2000.
71. Yoshioka S, Takahashi Y, Okimura Y, Takahashi K, Iguchi G, Iida K,
Kaji H, Chihara K. Gene expression profile in the heart of spontaneous
dwarf rat: in vivo effects of growth hormone. Biochem Biophys Res
Commun 341: 88–93, 2006.
277IDCM: HUMAN SEX-SPECIFIC cDNA ARRAY
Physiol Genomics • VOL 33 • www.physiolgenomics.org
Downloaded from journals.physiology.org/journal/physiolgenomics (073.004.114.249) on July 15, 2021.
